Needham & Company Reiterates Buy Rating, $36 Price Target on Collegium Pharmaceutical (COLL), Believes "COLL's Current Valuations Fails to Capture Growth Prospects"
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $36.00 price target on Collegium Pharmaceutical (NASDAQ: COLL), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
